Endometrial hyperplasia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Endometrial hyperplasia}}
{{Endometrial hyperplasia}}
{{CMG}} {{AE}} {{STM}}
{{CMG}} {{AE}} {{Badria}} , {{STM}}


==Overview==
==Overview==
Endometrial hyperplasia must be differentiated from conditions that have a similar [[ultrasound]] findings such as normal thickening during the secretory phase, [[sessile]] [[endometrial polyp]], submucosal uterine [[fibroid]]s, [[endometrial cancer]], an adherent intrauterine blood clot, and [[pregnancy]].<ref name="pmid8184058">{{cite journal| author=Hulka CA, Hall DA, McCarthy K, Simeone JF| title=Endometrial polyps, hyperplasia, and carcinoma in postmenopausal women: differentiation with endovaginal sonography. | journal=Radiology | year= 1994 | volume= 191 | issue= 3 | pages= 755-8 | pmid=8184058 | doi=10.1148/radiology.191.3.8184058 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8184058  }} </ref><ref name=wp>Endometrial hyperplasia. Radiopedia. http://radiopaedia.org/articles/endometrial-hyperplasia-1 Accessed on March 3, 2016.</ref><ref name=ol>Abnormally thickened endometrium: differential diagnosis. Radiopedia. http://radiopaedia.org/articles/abnormally-thickened-endometrium-differential-diagnosis Accessed on March 3, 2016.</ref>
Endometrial hyperplasia must be differentiated from conditions that have a similar [[ultrasound]] findings such as normal thickening during the secretory phase, [[sessile]] [[endometrial polyp]], submucosal uterine [[fibroid]]s, [[endometrial cancer]], an adherent intrauterine blood clot, and [[pregnancy]].
 
==Differential Diagnosis==
==Differential Diagnosis==
*Endometrial hyperplasia must be differentiated from the following conditions that have abnormal thickening of the [[uterus]]:<ref name="pmid8184058">{{cite journal| author=Hulka CA, Hall DA, McCarthy K, Simeone JF| title=Endometrial polyps, hyperplasia, and carcinoma in postmenopausal women: differentiation with endovaginal sonography. | journal=Radiology | year= 1994 | volume= 191 | issue= 3 | pages= 755-8 | pmid=8184058 | doi=10.1148/radiology.191.3.8184058 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8184058  }} </ref><ref name=wp>Endometrial hyperplasia. Radiopedia. http://radiopaedia.org/articles/endometrial-hyperplasia-1 Accessed on March 3, 2016.</ref><ref name=ol>Abnormally thickened endometrium: differential diagnosis. Radiopedia. http://radiopaedia.org/articles/abnormally-thickened-endometrium-differential-diagnosis Accessed on March 3, 2016.</ref>
*Endometrial hyperplasia must be differentiated from the following conditions that have abnormal thickening of the [[uterus]]:<ref name="pmid8184058">{{cite journal| author=Hulka CA, Hall DA, McCarthy K, Simeone JF| title=Endometrial polyps, hyperplasia, and carcinoma in postmenopausal women: differentiation with endovaginal sonography. | journal=Radiology | year= 1994 | volume= 191 | issue= 3 | pages= 755-8 | pmid=8184058 | doi=10.1148/radiology.191.3.8184058 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8184058  }} </ref><ref name=wp>Endometrial hyperplasia. Radiopedia. http://radiopaedia.org/articles/endometrial-hyperplasia-1 Accessed on March 3, 2016.</ref><ref name=ol>Abnormally thickened endometrium: differential diagnosis. Radiopedia. http://radiopaedia.org/articles/abnormally-thickened-endometrium-differential-diagnosis Accessed on March 3, 2016.</ref>
Line 23: Line 22:
*Intrauterine adhesions (irregular echogenic areas with focal thickening)
*Intrauterine adhesions (irregular echogenic areas with focal thickening)


Potential biomarker use — Considerable progress has been made in the evaluation of immunohistochemical markers to distinguish atypical hyperplasia from endometrial carcinoma. Two small pathology reviews noted that the absence of PAX2 expression on immunohistochemistry was helpful in delineating EIN [21], especially when there was a background of secretory endometrium [22]. PAX2 alterations were noted to correlate well with EIN, but were less useful with the WHO classification.
===Potential biomarkers===
 
* The absence of PAX2 expression on immunohistochemistry was helpful in delineating EIN<ref name="pmid23086768">{{cite journal |vauthors=Quick CM, Laury AR, Monte NM, Mutter GL |title=Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia |journal=Am. J. Clin. Pathol. |volume=138 |issue=5 |pages=678–84 |date=November 2012 |pmid=23086768 |doi=10.1309/AJCP8OMLT7KDWLMF |url=}}</ref><ref name="pmid10699996">{{cite journal |vauthors=Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC |title=Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry |journal=J. Pathol. |volume=190 |issue=4 |pages=462–9 |date=March 2000 |pmid=10699996 |doi=10.1002/(SICI)1096-9896(200003)190:4<462::AID-PATH590>3.0.CO;2-D |url=}}</ref><ref name="pmid22317873">{{cite journal |vauthors=Allison KH, Upson K, Reed SD, Jordan CD, Newton KM, Doherty J, Swisher EM, Garcia RL |title=PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia |journal=Int. J. Gynecol. Pathol. |volume=31 |issue=2 |pages=151–159 |date=March 2012 |pmid=22317873 |pmc=4646427 |doi=10.1097/PGP.0b013e318226b376 |url=}}</ref><ref name="pmid24556060">{{cite journal |vauthors=Laas E, Ballester M, Cortez A, Gonin J, Daraï E, Graesslin O |title=Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer |journal=Gynecol. Oncol. |volume=133 |issue=2 |pages=205–10 |date=May 2014 |pmid=24556060 |doi=10.1016/j.ygyno.2014.02.018 |url=}}</ref>
As an example, in a blind review of 206 endometrial samples, the percentage of cases with complete PAX2 loss (no cells staining) increased with increasing severity of hyperplasia: normal proliferative and secretory (no cases), simple hyperplasia (17.4 percent), complex hyperplasia (59 percent), atypical hyperplasia (74.1 percent), and grade 1 endometrioid carcinomas (73.3 percent) [23]. Another small immunohistochemistry assessment noted that various clusters of proteins, including MMP-9 and BCL-2 overexpression and estrogen and progesterone receptor underexpression, were useful to differentiate endometrial carcinoma from atypical endometrial hyperplasia [24].<ref name="pmid23086768">{{cite journal |vauthors=Quick CM, Laury AR, Monte NM, Mutter GL |title=Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia |journal=Am. J. Clin. Pathol. |volume=138 |issue=5 |pages=678–84 |date=November 2012 |pmid=23086768 |doi=10.1309/AJCP8OMLT7KDWLMF |url=}}</ref><ref name="pmid10699996">{{cite journal |vauthors=Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC |title=Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry |journal=J. Pathol. |volume=190 |issue=4 |pages=462–9 |date=March 2000 |pmid=10699996 |doi=10.1002/(SICI)1096-9896(200003)190:4<462::AID-PATH590>3.0.CO;2-D |url=}}</ref><ref name="pmid22317873">{{cite journal |vauthors=Allison KH, Upson K, Reed SD, Jordan CD, Newton KM, Doherty J, Swisher EM, Garcia RL |title=PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia |journal=Int. J. Gynecol. Pathol. |volume=31 |issue=2 |pages=151–159 |date=March 2012 |pmid=22317873 |pmc=4646427 |doi=10.1097/PGP.0b013e318226b376 |url=}}</ref><ref name="pmid24556060">{{cite journal |vauthors=Laas E, Ballester M, Cortez A, Gonin J, Daraï E, Graesslin O |title=Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer |journal=Gynecol. Oncol. |volume=133 |issue=2 |pages=205–10 |date=May 2014 |pmid=24556060 |doi=10.1016/j.ygyno.2014.02.018 |url=}}</ref>
* MMP-9
 
* BCL-2 overexpression
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Revision as of 16:25, 22 February 2019

Endometrial hyperplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Endometrial hyperplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Case Studies

Case #1

Endometrial hyperplasia differential diagnosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Endometrial hyperplasia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Endometrial hyperplasia differential diagnosis

CDC on Endometrial hyperplasia differential diagnosis

Endometrial hyperplasia differential diagnosis in the news

Blogs on Endometrial hyperplasia differential diagnosis

Directions to Hospitals Treating Endometrial hyperplasia

Risk calculators and risk factors for Endometrial hyperplasia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Badria Munir M.B.B.S.[2] , Soujanya Thummathati, MBBS [3]

Overview

Endometrial hyperplasia must be differentiated from conditions that have a similar ultrasound findings such as normal thickening during the secretory phase, sessile endometrial polyp, submucosal uterine fibroids, endometrial cancer, an adherent intrauterine blood clot, and pregnancy.

Differential Diagnosis

  • Endometrial hyperplasia must be differentiated from the following conditions that have abnormal thickening of the uterus:[1][2][3]

Pregnancy related

Non-pregnancy related

  • Endometrial carcinoma (variable appearance)
  • Endometrial polyp or polyps (usually hyperechoic, often focal, look for vascular stalk)
  • Submucosal uterine fibroids
  • Intrauterine adhesions (irregular echogenic areas with focal thickening)

Potential biomarkers

  • The absence of PAX2 expression on immunohistochemistry was helpful in delineating EIN[4][5][6][7]
  • MMP-9
  • BCL-2 overexpression

References

  1. Hulka CA, Hall DA, McCarthy K, Simeone JF (1994). "Endometrial polyps, hyperplasia, and carcinoma in postmenopausal women: differentiation with endovaginal sonography". Radiology. 191 (3): 755–8. doi:10.1148/radiology.191.3.8184058. PMID 8184058.
  2. Endometrial hyperplasia. Radiopedia. http://radiopaedia.org/articles/endometrial-hyperplasia-1 Accessed on March 3, 2016.
  3. Abnormally thickened endometrium: differential diagnosis. Radiopedia. http://radiopaedia.org/articles/abnormally-thickened-endometrium-differential-diagnosis Accessed on March 3, 2016.
  4. Quick CM, Laury AR, Monte NM, Mutter GL (November 2012). "Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia". Am. J. Clin. Pathol. 138 (5): 678–84. doi:10.1309/AJCP8OMLT7KDWLMF. PMID 23086768.
  5. Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC (March 2000). "Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry". J. Pathol. 190 (4): 462–9. doi:10.1002/(SICI)1096-9896(200003)190:4<462::AID-PATH590>3.0.CO;2-D. PMID 10699996.
  6. Allison KH, Upson K, Reed SD, Jordan CD, Newton KM, Doherty J, Swisher EM, Garcia RL (March 2012). "PAX2 loss by immunohistochemistry occurs early and often in endometrial hyperplasia". Int. J. Gynecol. Pathol. 31 (2): 151–159. doi:10.1097/PGP.0b013e318226b376. PMC 4646427. PMID 22317873.
  7. Laas E, Ballester M, Cortez A, Gonin J, Daraï E, Graesslin O (May 2014). "Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer". Gynecol. Oncol. 133 (2): 205–10. doi:10.1016/j.ygyno.2014.02.018. PMID 24556060.

Template:WikiDoc Sources